BERGER RONALD 5

Accession 0001144204-13-008186

CIK 0001175151other

View on SEC.gov Company Profile

Filed

Feb 12, 7:00 PM ET

Accepted

Feb 13, 3:56 PM ET

Size

30.2 KB

Accession

0001144204-13-008186

Insider Transaction Report

Form 5

Period: 2012-12-31

Cytosorbents CorpCTSO

BERGER RONALD

See Remarks

Transactions

Purchase
Common Stock, par value $0.001 per share
2006-08-11$3.72/sh+500$1,860→ 6,500 total(indirect: By Spouse)
Purchase
Common Stock, par value $0.001 per share
2007-08-27$0.55/sh+5,000$2,750→ 6,500 total(indirect: By Spouse)
Purchase
Series B Preferred Stock
2009-10-05+68.83→ 68.83 total
Exercise: $0.04→ Common Stock, par value $0.001 per share (190,138 underlying)
Purchase
Convertible Note
2010-10-22$0.10/sh→ 0 total
Exercise: $0.10Exp: 2012-10-22→ Common Stock, par value $0.001 (58,011 underlying)
Purchase
Warrants
2010-10-22+43,333→ 43,333 total
→ Common Stock, par value $0.001 (43,333 underlying)
Award
Stock Options
2010-01-04+15,000→ 153,000 total
Exercise: $0.17From: 2010-01-04Exp: 2015-01-04→ Common Stock, par value $0.001 per share (15,000 underlying)
Award
Stock Options
2009-01-28+15,000→ 153,000 total
Exercise: $0.17From: 2009-01-28Exp: 2014-01-28→ Common Stock, par value $0.001 per share (15,000 underlying)
Purchase
Common Stock, par value $0.001 per share
2007-06-21$0.55/sh+1,000$550→ 6,500 total(indirect: By Spouse)
Award
Stock Options
2012-01-18+30,000→ 153,000 total
Exercise: $0.17From: 2012-01-18Exp: 2017-01-18→ Common Stock, par value $0.001 per share (30,000 underlying)
Award
Stock Options
2008-01-16+9,000→ 153,000 total
Exercise: $0.25From: 2008-01-16Exp: 2013-01-16→ Common Stock, par value $0.001 per share (9,000 underlying)
Award
Stock Options
2011-01-06+75,000→ 153,000 total
Exercise: $0.14From: 2011-01-06Exp: 2016-01-06→ Common Stock, par value $0.001 per share (75,000 underlying)
Award
Stock Options
2008-06-25+9,000→ 153,000 total
Exercise: $0.04From: 2008-06-25Exp: 2013-06-25→ Common Stock, par value $0.001 per share (9,000 underlying)

Footnotes (7)

[F1]The conversation rate of these securities is one share of the Issuer's Common Stock for each $0.0362 of stated value or accrued but unpaid dividends being converted, subject to adjustment. Each share of the Series B Preferred Stock has a stated value of $100.
[F2]Immediately exercisable.
[F3]Not applicable.
[F4]The convertible note has expired as of October 22, 2012. Accordingly, the note is convertible into 58,011 shares of Common Stock (the aggregate amount of principal plus accrued interest) at maturity. The Company has not yet issued the corresponding shares, however, intends to do so promptly.
[F5]In connection with the Convertible Note, Ronald Berger holds the following warrants: (i) 8,333 warrants with an exercise price of $0.15, (ii) 10,000 warrants with an exercise price of $0.125, and (iii) 25,000 warrants with an exercise price of $0.10.
[F6]The stock options were issued as compensation for services rendered.
[F7]Includes all of the options to purchase Common Stock by Ronald Berger.

Documents

1 file

5
v335034_5.xmlPrimary
OWNERSHIP DOCUMENT

Issuer

Cytosorbents Corp

CIK 0001175151

→

Entity typeother

Related Parties

filerCIK 0001569283

Filing Metadata

Form type: 5
Filed: Feb 12, 7:00 PM ET
Accepted: Feb 13, 3:56 PM ET
Size: 30.2 KB

View on SEC.gov